selected publications
-
Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
Pediatric blood & cancer.
2015
Academic Article
GET IT
Times cited: 68 -
Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
Pediatric blood & cancer.
2013
Academic Article
GET IT
Times cited: 20 -
Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Pediatric blood & cancer.
2010
Academic Article
GET IT
Times cited: 15 -
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 71 -
Early breast cancer therapy and cardiovascular injury.
Journal of the American College of Cardiology.
2008
Article
GET IT
Times cited: 3 -
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2006
Academic Article
GET IT
Times cited: 201 -
Using health-related quality of life measures to predict cardiac function in survivors exposed to anthracyclines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2004
Academic Article
GET IT
Times cited: 17 -
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2004
Academic Article
GET IT
Times cited: 209 -
Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers.
Medical and pediatric oncology.
2003
Academic Article
GET IT
Times cited: 32 -
Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2003
Academic Article
GET IT
Times cited: 45 -
Presence of prolonged dispersion of qt intervals in late survivors of childhood anthracycline therapy.
Pediatric hematology and oncology.
2002
Academic Article
GET IT
Times cited: 15 -
Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors.
American heart journal.
2001
Academic Article
GET IT
Times cited: 32 -
A Phase II clinical trial of idarubicin administered to children with relapsed brain tumors.
Cancer.
1998
Academic Article
GET IT
Times cited: 19 -
Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Medical and pediatric oncology.
1996
Academic Article
GET IT
Times cited: 32 -
Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients.
Medical and pediatric oncology.
1995
Academic Article
GET IT
Times cited: 184 -
Guidelines for monitoring of anthracycline cardiomyopathy: a rebuttal.
Pediatrics.
1994
Article
GET IT
Times cited: 10 -
A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children.
Journal of pediatric surgery.
1994
Academic Article
GET IT
Times cited: 38 -
Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
Cancer.
1993
Academic Article
GET IT
Times cited: 89 -
Sick sinus syndrome in a teenager treated with idarubicin.
Journal of cardiothoracic and vascular anesthesia.
1993
Article
GET IT
Times cited: 4 -
Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
Medical and pediatric oncology.
1992
Academic Article
GET IT
Times cited: 11 -
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
JAMA.
1991
Academic Article
GET IT
Times cited: 847 -
Delayed cardiac toxicity from anthracycline therapy.
Pediatrician.
1991
Academic Article
GET IT
Times cited: 48 -
Phase I trial of homoharringtonine in children with refractory leukemia.
Cancer treatment reports.
1987
Academic Article
GET IT
Times cited: 17 -
Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Cancer research.
1987
Academic Article
GET IT
Times cited: 36 -
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Cancer research.
1982
Academic Article
GET IT
Times cited: 15 -
Cardiac abnormalities after AMSA administration.
Cancer treatment reports.
1982
Academic Article
GET IT
Times cited: 25 -
Cardiac changes with cyclophosphamide.
Medical and pediatric oncology.
1981
Academic Article
GET IT
Times cited: 76 -
Phase I trial of rubidazone (NSC 164011) in children with cancer.
Medical and pediatric oncology.
1981
Academic Article
GET IT
Times cited: 5 -
Membranous subaortic stenosis and patent ductus arteriosus.
Chest.
1977
Academic Article
GET IT
Times cited: 10 -
Recent advances in the diagnosis and treatment of congenital heart disease.
Southern medical journal.
1977
Information Resource
GET IT
Times cited: 1